Skip to content

Author

Johnny Mahlangu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#gene editing Review Oct 2026

Designing for success in early phase haemophilia clinical trials: historical lessons and emerging principles for next generation therapeutics.

INTRODUCTION Hemophilia drug development has progressed through five therapeutic eras: plasma-derived concentrates, recombinant proteins, extended-half-life molecules, non-factor rebalancing agents, and gene therapy. Each transition depended not only on molecular innovation but also on early-phase trials that addressed...

Johnny Mahlangu · 0 citations
Review Sep 2026

Long-term safety of treatment of hemophilia A: a comprehensive review.

INTRODUCTION Hemophilia A is an inherited bleeding disorder due to factor VIII (FVIII) deficiency and is characterized by recurrent bleeding and progressive joint damage. For the last two decades, treatment strategies have expanded from FVIII replacement therapy to include extended half-life products, non-factor therap...

Johnny Mahlangu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.